An Intrapatient Dosimetry Comparison of<sup>177</sup>Lu-rhPSMA-10.1 and<sup>177</sup>Lu-PSMA-I&T in Patients with Metastatic Castration-Resistant Prostate Cancer-Reference-Cited by-同舟云学术

An Intrapatient Dosimetry Comparison of¹⁷⁷Lu-rhPSMA-10.1 and¹⁷⁷Lu-PSMA-I&T in Patients with Metastatic Castration-Resistant Prostate Cancer

Published:2023-09-28 Issue:12 Volume:64 Page:1918-1924
ISSN:0161-5505
Container-title:Journal of Nuclear Medicine
language:en
Short-container-title:J Nucl Med

Author:

Rinscheid Andreas,Gäble Alexander,Wienand Georgine,Pfob Christian,Dierks Alexander,Kircher Malte,Trepel Martin,Weckermann Dorothea,Lapa Constantin,Bundschuh Ralph A.

Publisher

Society of Nuclear Medicine

Subject

Radiology, Nuclear Medicine and imaging

Reference30 articles.

1. [ 177 Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study

2. Treatment outcome, toxicity, and predictive factors for radioligand therapy with 177Lu-PSMA-I&T in metastatic castration-resistant prostate cancer;Heck;Eur Urol.,2019

3. Pre-therapeutic comparative dosimetry of 177Lu-rhPSMA-7.3 and 177Lu-PSMAI&T in patients with metastatic castration resistant prostate cancer (mCRPC)

4. Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer

5. Hennrich U Eder M . [177Lu]Lu-PSMA-617 (PluvictoTM): the first FDA-approved radiotherapeutical for treatment of prostate cancer. Pharmaceuticals (Basel). 2022;15:1292.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Developmental Therapeutics in Metastatic Prostate Cancer: New Targets and New Strategies;Cancers;2024-09-06

2. Theranostics: Timing is Everything;Cancer Biotherapy and Radiopharmaceuticals;2024-05-17

3. First Safety and Efficacy Data with the Radiohybrid¹⁷⁷Lu-rhPSMA-10.1 for the Treatment of Metastatic Prostate Cancer;Journal of Nuclear Medicine;2023-12-21